{"name":"Molecular Targeting Technologies, Inc.","slug":"molecular-targeting-technologies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"177Lu-DOTA-EB-TATE","genericName":"177Lu-DOTA-EB-TATE","slug":"177lu-dota-eb-tate","indication":"Neuroendocrine tumors","status":"phase_1"}]}],"pipeline":[{"name":"177Lu-DOTA-EB-TATE","genericName":"177Lu-DOTA-EB-TATE","slug":"177lu-dota-eb-tate","phase":"phase_1","mechanism":"Somatostatin receptor targeting","indications":["Neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOUXVLRkhqdlZBVDZORC1IbGk5bmdOSkhFdXlhYmRmeFdXcFJQODFfSEh5anNmZE9EOGRWM3RKa1JILUlCbWlaVGM4UGkweF94ZmRBc1VVSHB0TXZnZzNtUDNsMEtBYlR3enl3MmhVZlptcllGY0RaWHNjam4zS0dsSFFjNWFrZENnejFYbg?oc=5","date":"2026-01-23","type":"pipeline","source":"Manufacturing Chemist","summary":"MetP Pharma unveils brain-targeted intranasal GLP-1 delivery technology - Manufacturing Chemist","headline":"MetP Pharma unveils brain-targeted intranasal GLP-1 delivery technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSUFsUDBFVzQyNlc0UWxoRHk0WDlGR2tRZlF0Mk50Qk1kbEE0clNZdTJLdGVVa2VxeEJ4VGg2aTB1ZEk1aE1pdTZzREFENmFYVDN3amQxOUhacUlvMUtfYmI1TWZrUmdsV2xYblNsd19JRDVFRWdGSFd1aHNlSGY5LUEtZzRIOXVjTkFtU0RwS1ExTUpl?oc=5","date":"2025-10-27","type":"pipeline","source":"Yahoo Finance","summary":"Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Yahoo Finance","headline":"Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-27","type":"regulatory","source":"PR Newswire","summary":"Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib ","headline":"Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Thi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOZFJwMUFuaUNmOFQ2R3RkbDByRGMyYjNEMUpRaWp4cW5ISjN0RDFOTEMxSENSQ1ZyTVFtd2g0NUQzSjYwUjNrVjVuU0RBRW1hN0dKbUJTaXVEREVuZUpVbTlWSURIcWR1Mjd2VG8xaktTYk9vVHYtNzdHQ3IyR0g4V1V4UHRUNFRCQ01lQnNYS203UUp5dFVfMVJwSDJHWmlHQnlNeVE5Rk1CMXBKSGhvSDhpU0ZyUzNPdy1YUWJmdEx0ZUptZXhwckRqbU5oWEFZRGRuQ3AxVFdHSWR6V01tNHA1Vy1EekwzVk1PLTBCN0otalAzMGF2UDZqbkV3aXFCNm8teTFvZURhVWFqUEM1bUhrQkhIaEZNUzBBUUJFOWM2YURkX3VIWFNR?oc=5","date":"2025-10-14","type":"pipeline","source":"businesswire.com","summary":"Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Targeted Radiotherapeutic (EB-TRT) - businesswire.com","headline":"Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNaEFZYnRrZFFBOUpQVjFGc2w3R0oyM2VTV2hoSE5hUU5uM1gyX2R0ZWxQNFRlcHVHc21uQXo0V3RuR2sxTVN5NjRLUFpPTWlJaWxjNUMxSmdFYnUwZ2Y4R194WHZyMzFXRTNqZExYRXJMTVZXWVBvVExLeGVZaDJSbWhrRElOLVZ6amVxUE9SYkM2NmVoU1BTSTFWZUZaQ1dMaVlGUXliOHI?oc=5","date":"2025-10-14","type":"deal","source":"Fierce Pharma","summary":"Halozyme CEO targets new deals as IRA uncertainty subsides - Fierce Pharma","headline":"Halozyme CEO targets new deals as IRA uncertainty subsides","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"trial","source":"PR Newswire","summary":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Confer","headline":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOU1JOTV9fRk80U3dfQUdRRF9nb1lvTzdaMWRXaE9FOFExbnUxYXFXc01rblg3QUVvbXI5RlpSR2RTYXpsb0t2WlpBVE9PSFpEOUtrWHFxcmRpQXZncElacHd2bXNHZkkyeVVNVE5nU2JfM3FyUEVKYXFwd1I0VTBxeGd6Q0VmR1RtUGIyNkQ4a2FrdThOdG9ZVmY3bmhwUQ?oc=5","date":"2025-08-12","type":"pipeline","source":"The Healthcare Technology Report.","summary":"The Top 25 Biotech and Life Sciences Companies of 2025 - The Healthcare Technology Report.","headline":"The Top 25 Biotech and Life Sciences Companies of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVndjUlJXYTAzSHdZb1BpZnh4WUpObkZUa0Z3dDRCUGJ2VEJkVnU3elQySnQyQzZ6NmVXVGl4ZWJFVkpvNGNHX09SOTZ3OXhodmlKSjUzM2FjNVl4M0JjRXhWS3NqeVJCQnM4dmwxcGwtQzY2RXYzT3phb3V0WWwtQTJGUlZmbWc?oc=5","date":"2025-07-22","type":"pipeline","source":"Yahoo Finance","summary":"MTTI Announces Dr. Danielle Meyrick to Lead Medical Team - Yahoo Finance","headline":"MTTI Announces Dr. Danielle Meyrick to Lead Medical Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRVozZ1c4Q1JIYWNzNjMyUzYyekttbUM3M0prbkYyZzJkOWsyY1pvU2hOdUViekxrT0FwV05OWC1UT19lWndaQ2hDZ25FWUFBX2Y1VmlnWHdaSG5DVk01LXJUX3RZYVJlbUVtS1lWckhvUTk5cURnZlNYaGVDbHJ2QkVZMWhNa2c2dlIzY2YteXJqN05pWUpTVXJGQkh0a3hlUmhuaGtkT3lTWTFnNndzMGhkaTF5VUpiMUJpN0xLRFJVeGJqdHBBeVdNRGxpU2FZMEM3b3RMMjdmQQ?oc=5","date":"2025-07-08","type":"regulatory","source":"Biotech Newswire","summary":"MetP® Technology Unlocks Intranasal Delivery of Semaglutide and Other Brain-Targeting Peptides - Biotech Newswire","headline":"MetP® Technology Unlocks Intranasal Delivery of Semaglutide and Other Brain-Targeting Peptides","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQbGM0N0FGTjRlVWw3Mld5RzVNWHNxWXp5dWItMzJ4Wkw1TS1rM2JoN0Z4M1h4T2NJNV82V0xxSFJmRzlqZVpBY3JBX094QzJJQlpPRWJjc05TQmNhUGhwYmtlWnNjYlNiR0FYZVZJVjhlM0o0MjVScEtrTlJCR2Z6c0NLLVZUdUIx?oc=5","date":"2025-06-09","type":"pipeline","source":"PharmTech.com","summary":"Achieving Targeted Delivery with Nanoscale Systems - PharmTech.com","headline":"Achieving Targeted Delivery with Nanoscale Systems","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNUmFlR0ViNjhxb0ZnaE5CMzByY2pFOHU3dzVnZ0NuZV9sX0NodElMUm00aHJOYWRQU3pNSVdBelp6XzA0ZWlQQWlYOHk4bXlnZGtTMTlTalhoQ1pOLU80b1VPWHQ0RW4xRUFHbjQ4bjNpeW9LUGRuZFN6T0lvY2JkdUtUTWE0RXBqMXVaVWNsZnNIdW9kalExajlxMWhCTzI1ZWR3dFFWY2NmbzZXZXpKUVQwV1UyOG5BOG00dzZvRHd5Nmtxd1FsVTdvU3lmM0pWQjl5M0JRaHVNQ2FEN1JlTE5UdlE5TVVrQUZkRUpoYngwZVROdkczOFlvZkVXYWlSdEZFeHZwNUZETFpoMmI0NHJQUW0xakdpOFAxWEVZbE9oSjR4S2Vn?oc=5","date":"2025-06-04","type":"pipeline","source":"GlobeNewswire","summary":"Molecular Health and Axxam enter into a strategic - GlobeNewswire","headline":"Molecular Health and Axxam enter into a strategic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcWtXTVAxWnh1ckV6YlhTd1ZaLW9qUXRWMFktYmE4bFZKMThJdlVPWWtLNU9mbWxVT3Bmd1B4ZnZfMzI0bEVQckJiNF9TVE9PVzJnTndBZWFXdTFubGdBdE03SWxBTmNFT2htc0p1NEc0aU5BS1FvNXZ0RHphN1huVXdqbmx0UlpXVGNBMmU2amJHTWE1cHNhZVhGVzcxMy1aWGc1bk5DU3Buc0lHdmJnWjlZVlpSb3lFTklGQ2d5cEE?oc=5","date":"2025-05-28","type":"pipeline","source":"Clarivate","summary":"Pharma Bets Bigger on Fewer Strategic Assets & Platforms - Clarivate","headline":"Pharma Bets Bigger on Fewer Strategic Assets & Platforms","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}